drugset / Trial / NCT05949541
Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a randomized, controlled, open-label, phase II study to explore the efficacy and safety of Everolimus in combination with standard first-line endocrine therapy for the HR+/ HER2-SNF1 subtype of advanced breast cancer. The study was used to explore the efficacy of Everolimus in combination with standard endocrine therapy.
Timeline
- Start
- 2023-07-26
- Primary completion
- 2026-07
- Completion
- 2028-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Everolimus | Small molecule | 10 mg | Oral |
| Background | Anastrozole | Other / unclassified | 1 mg | Oral |
| Background | Dalpiciclib | Small molecule | 125 mg | Oral |
| Background | Exemestane | Small molecule | 25 mg | Oral |
| Background | Fulvestrant | Small molecule | 500 mg | Intramuscular |
| Background | Goserelin | Other / unclassified | 3.6 mg | Subcutaneous |
| Background | Letrozole | Other / unclassified | 2.5 mg | Oral |